Evidence map›Paper›PMID 33539255›Full record

ArticleEmerging microbes & infections2021

Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.

Awadalkareem Adam, Huanle Luo, Samantha R Osman, Binbin Wang, Christopher M Roundy, Albert J Auguste, Kenneth S Plante, Bi-Hung Peng, Saravanan Thangamani, Elena I Frolova and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Awadalkareem AdamDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Huanle LuoDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Samantha R OsmanDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Binbin WangDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Christopher M RoundyDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Albert J AugusteDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Kenneth S PlanteWorld Reference Center for Emerging Viruses and Arboviruses, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Bi-Hung PengDepartment of Neuroscience, Cell Biology and Anatomy, University of Texas Medical Branch, Galveston, TX, USA.
Saravanan ThangamaniDepartment of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
Elena I FrolovaDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ilya FrolovDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Scott C WeaverDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Tian WangDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID https://orcid.org/0000-0002-1511-0793
The University of Texas Medical Branch at Galveston · USUniversity of Alabama at Birmingham · USSUNY Upstate Medical University · US

Funding

Revolutionary Eilat-based Chikungunya Vaccine VectorR01AI127744 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WANG, TIAN · 2017 to 2021
$3.5M
A Novel Strategy for Generating Safe and Effective Flavivirus VaccinesR01AI153433 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI AUGUSTE, ALBERT J. · 2020 to 2024
$2.0M
NIAID NIH HHS R01 AI127744NIAID NIH HHS R01 AI153433
6 · The paper itself

Abstract

A chimeric Eilat/ Chikungunya virus (EILV/CHIKV) was previously reported to replicate only in mosquito cells but capable of inducing robust adaptive immunity in animals. Here, we initially selected C7/10 cells to optimize the production of the chimeric virus. A two-step procedure produced highly purified virus stocks, which was shown to not cause hypersensitive reactions in a mouse sensitization study. We further optimized the dose and characterized the kinetics of EILV/CHIKV-induced immunity. A single dose of 10

Indexed as

AnimalsAntibodies, ViralCD8-Positive T-LymphocytesCell Culture TechniquesCell LineChikungunya FeverChikungunya virusCulicidaeFemaleHumansMiceViral VaccinesAntibodies, ViralViral VaccinesChikungunya virusimmunityinsectsafetyVaccine

Identifiers

PMID33539255
PMCPMC7919884
OpenAlexW3127518202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.